ZA200403278B - Rehydrating formulation. - Google Patents
Rehydrating formulation. Download PDFInfo
- Publication number
- ZA200403278B ZA200403278B ZA200403278A ZA200403278A ZA200403278B ZA 200403278 B ZA200403278 B ZA 200403278B ZA 200403278 A ZA200403278 A ZA 200403278A ZA 200403278 A ZA200403278 A ZA 200403278A ZA 200403278 B ZA200403278 B ZA 200403278B
- Authority
- ZA
- South Africa
- Prior art keywords
- aqueous formulation
- concentration
- range
- galactose
- formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 32
- 238000009472 formulation Methods 0.000 title claims description 19
- 239000013011 aqueous formulation Substances 0.000 claims description 80
- 229930182830 galactose Natural products 0.000 claims description 54
- 208000005156 Dehydration Diseases 0.000 claims description 36
- 230000018044 dehydration Effects 0.000 claims description 36
- 238000006297 dehydration reaction Methods 0.000 claims description 36
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 33
- 239000008103 glucose Substances 0.000 claims description 31
- 150000001720 carbohydrates Chemical class 0.000 claims description 24
- 229910001415 sodium ion Inorganic materials 0.000 claims description 23
- 235000014633 carbohydrates Nutrition 0.000 claims description 20
- 206010012735 Diarrhoea Diseases 0.000 claims description 18
- 239000011734 sodium Substances 0.000 claims description 16
- 229910052708 sodium Inorganic materials 0.000 claims description 16
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 14
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 12
- 150000002500 ions Chemical class 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 229920001542 oligosaccharide Polymers 0.000 claims description 6
- 150000002482 oligosaccharides Chemical class 0.000 claims description 6
- 239000005913 Maltodextrin Substances 0.000 claims description 5
- 229920002774 Maltodextrin Polymers 0.000 claims description 5
- 229940035034 maltodextrin Drugs 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 229910001414 potassium ion Inorganic materials 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 11
- 230000007812 deficiency Effects 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 7
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 231100000249 enterotoxic Toxicity 0.000 description 4
- 230000002242 enterotoxic effect Effects 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 206010008631 Cholera Diseases 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 241000702670 Rotavirus Species 0.000 description 3
- 229960003624 creatine Drugs 0.000 description 3
- 239000006046 creatine Substances 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 206010014418 Electrolyte imbalance Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 240000001890 Ribes hudsonianum Species 0.000 description 2
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 2
- 235000001466 Ribes nigrum Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 240000001717 Vaccinium macrocarpon Species 0.000 description 2
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 2
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 235000004634 cranberry Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000002727 hyperosmolar Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000006362 insulin response pathway Effects 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000011496 sports drink Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 244000148687 Glycosmis pentaphylla Species 0.000 description 1
- 208000029422 Hypernatremia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 244000093965 Triphasia trifolia Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- -1 preferably glucose Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pediatric Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Description
REHYDRATING FORMULATION
) The present invention relates to an aqueous formulation for combatting . dehydration comprising a low concentration of galactose and a source of sodium ions (eg a w sodium salt).
There are a number of circumstances in which a subject may suffer dehydration and associated deficiencies such as loss of mineral salts. For example, exercise acts to deplete the body of fuel stores and increases the rate of perspiration causing loss of water ) and mineral salts. These losses can be significant if exercise is prolonged and particularly if ambient temperatures are moderate or high. Other circumstances which may lead to : dehydration include excessive temperatures, nutritional deprivation, fever, diarrhoea and vomiting excess as a result of (for example) enterotoxin effects (eg cholera typically in the ‘ third world), viral effects (eg rotavirus typically in the developed world) or post surgical rest (eg when GI rest is important). Alternatively, the circumstances which may lead to dehydration may be self-induced (eg through alcohol consumption). In extreme cases, loss of fluid and/or electrolytes may be clinically important or even life threatening, in particular in children and the elderly.
Humans do not function efficiently when dehydrated or when they are suffering an electrolyte imbalance. Rehydrating drinks containing inorganic salts and/or high sugar (eg glucose) content are well established in combatting these disorders. However the administration of glucose may lead to exaggerated insulin responses.
Galactose is a naturally occurring hexose for which worldwide demand is negligible and reported uses scarce. Prior publications relating to galactose include: (1) WO-A-01/28360 (Marathade Ltd) discloses high energy multi-saccharide food products containing galactose and creatine for use in sport or to combat hunger or fatigue; (2) EP-A-0340491(Biodyn Ag) discloses a foodstuff in which the saccharide component is primarily galactose;
CONFIRMATION COPY
(3) WO-A-96/18313 (University of Nottingham) discloses formulations for increasing creatine uptake comprising creatine, insulin and a simple carbohydrate such as galactose; (4) WO-A-98/06418 (Mannatech, Inc) discloses dietary supplements comprising galactose for nutritional support and treating various disorders; (5) US-A-5843921 (Childrens Hospital of Los Angeles) discloses formulations for treatment of diabetes comprising less than 3g per unit of simple sugars including galactose; (6) WO-A-96/08979 (Quadrant Holdings Cambridge Ltd) discloses sports beverages comprising trehalose and galactose; (7) WO-A-90/02494 (Svenska Mejeriernas Riksforening Ekonomi AB) discloses a sports drink comprising galactose originating from a desalinated and hydrolised whey concentrate; (8) EP-A-349712 (Biodyn Ag) discloses foodstuffs containing a tooth protecting amount of galactose in the form of lactose hydrosylate; and (9) EP-A-184121 (Biodyn Ag) discloses anti-caries additives for sucrose foodstuffs comprising galactose I.
US-A-5780094 (Marathade Limited) discloses a rehydrating sports drink containing a high concentration of galactose and a proportion of glucose. The absorption of water in the intestine is efficient and effective when driven by sodium co-transport involving a high concentration of galactose and glucose. Galactose advantageously effects more rapid intestinal uptake of water than does glucose.
The present invention is based on the recognition that being physiologically adapted to effectively metabolise galactose and glucose (the two constituent sugars of lactose in milk) children are able to exploit sodium co-transport for effective rehydration using a low concentration of galactose. In particular, the present invention relates to an improved rehydrating aqueous formulation comprising a low concentration of galactose and a sodium salt to combat dehydration resutting from (for example) diarrhoea.
Thus viewed from one aspect the present invention provides an aqueous formulation for combatting dehydration comprising galactose at a concentration in the range 25 to 135mM, a source of sodium ions and water.
The aqueous formulation of the invention is generally more effective than a conventional glucose-containing rehydrating solution in treating extreme dehydration ' which might otherwise be fatal to a child. Moreover galactose (unlike glucose) does not . elicit a primary insulin response.
In a preferred embodiment, the concentration of galactose in the aqueous formulation is in the range 25 to 130mM, preferably 37 to 120mM, more preferably 40 to 120mM, especially preferably 45 to 90mM. i The source of sodium ions in the aqueous formulation of the invention is typically a sodium salt. Any physiologically tolerable sodium salt will suffice. Examples include : sodium lactate, sodium chloride, sodium citrate, trisodium citrate, sodium hydrogenphosphate, disodium hydrogen phosphate and sodium bicarbonate. The counter : ion (eg chloride, bicarbonate, phosphate, hydrogenphosphate or citrate) may provide stability and buffering capacity and sodium citrate is advantageous for acidosis associated with diarrhoea of specific aetiology (eg viral). Sodium chloride is preferred.
The concentration of sodium ions may be adapted to facilitate sodium co-transport and replacement of electrolyte loss. In a preferred embodiment, the concentration of sodium ions in the aqueous formulation is in the range 25 to 100mM, preferably 30 to 90mM, particularly preferably 35 to 90mM, more preferably 45 to 90mM, yet more preferably 60 to 90mM. For combatting dehydration as a symptom of severe diarrhoea (eg caused by enterotoxin effects), higher sodium concentrations are preferred (eg 80-90mM such as about 90mM). For combatting dehydration as a symptom of less severe diarrhoea (eg caused by viral effects or when hypernatraemia is a risk), lower sodium concentrations are preferred.
An embodiment of the aqueous formulation further comprises one or more sources
Y of additional ions (eg potassium, magnesium, calcium or zinc) to advantageously achieve replacement of minerals which have been lost as a symptom of (for example) diarrhoea.
The source of an additional ion is typically a salt (eg a mineral salt) such as a chloride.
Preferably the aqueous formulation comprises a source of potassium ions (eg a potassium salt such as potassium chloride). The potassium salt serves to replace electrolyte loss. In a preferred embodiment, the concentration of potassium ions in the aqueous formulation is in the range 5 to 35mM, preferably 10 to 30mM, particularly preferably 15 to 25mM, more preferably about 20 to 25mM.
An embodiment of the aqueous formulation of the invention further comprises one or more additional carbohydrates. In an embodiment of the invention, the one or more additional carbohydrates may be a digestible saccharide such as a digestible saccharide selected from one or more of the group consisting of monosaccharides, disaccharides, oligosaccharides and polysaccharides. These may be natural or synthetic saccharides. For example, the one or more additional carbohydrates may be selected from the group consisting of glucose, sucrose, dextrose, fructose, lactose and maltose. Preferably the additional carbohydrate is a monosaccharide, particularly preferably glucose, In situations where the osmolality of the aqueous formulation is important (eg where hyperosmolar or isomolar solutions are contra indicated), maltodextrin or higher oligosaccharide may be used in place of glucose.
In a preferred embodiment, the galactose and optionally one or more additional carbohydrates of the aqueous formulation are present in a total amount sufficient to meet the carbohydrate requirements of sodium co-transport for effective rehydration. In a preferred embodiment, the total concentration of carbohydrate is in the range 50 to 300mM, preferably 50 to 200mM, particularly preferably 55 to 175mM, more preferably 60 to 135mM, especially preferably 90 to 130mM.
In a preferred embodiment of the formulation, galactose and glucose are present in a total amount sufficient to meet the carbohydrate requirements of sodium co-transport in effective rehydration. Typically the ratio of molar concentration of galactose and glucose is in the range 0.6:1 to 1:0.6, preferably 0.8:1 to 1:0.8, particularly preferably 0.9:1t0 1:0.9, more preferably the molar concentration ratio is about 1:1. :
In a preferred embodiment, the concentration of glucose in the aqueous formulation is in the range 30 to 135mM, preferably 35 to 130mM, particularly preferably 37 to 120mM, more preferably 40 to 100mM, especially preferably 45 to 80mM.
In situations where the osmolality of the aqueous formulation is important (eg where hyperosmolar or isomolar solutions are contra indicated), maltodextrin or higher oligosaccharide is preferably used in place of glucose. Thus the ranges of preferred glucose concentration may be satisfied by a concentration of an oligosaccharide with an appropriate chain length. For example, in place of glucose at 60mM, a maltodextrin of average chain . length six could be used at 10mM. ) A general purpose formulation might typically have a ratio of sodium ion concentration:carbohydrate concentration of about 1:2 eg a concentration of sodium ions of ) about 60mM and galactose and glucose present at a total concentration of 120mM. Such a formulation would be useful where the circumstance leading to dehydration is diarrhoea as a result of post surgical rest (eg when GI rest is important) or the circumstance leading to dehydration is self-induced (eg through alcohol consumption).
The aqueous formulation of the invention may be administered by any convenient route. Preferably the aqueous formulation is adapted for oral administration. For example, the aqueous formulation may be palatable and for this purpose may further comprise natural or synthetic flavourings such as fruit flavourings (eg blackcurrant, strawberry, apple, citrus, lemon, lime, orange or cranberry) or caffeine and sweeteners. :
The aqueous formulation of the invention may further comprise physiologically tolerable stabilisers, anti-oxidants (eg ascorbic acid) and preservatives (eg sodium benzoate or sorbic acid) as desired. oy The administration dosage generally depends on the level of dehydration and the size and age of the subject. Generally it is advisable for the dose to be equivalent to or slightly greater than the actual or expected loss of bodily water and to be administered at appropriate intervals. Typically a dose of aqueous formulation is in the range 100 to 250ml.
Citric acid may be added to the aqueous formulation for partial or total replacement of citrate ion and for buffering purposes (typically to maintain pH in the range 2 to 6). Where the source of sodium or other ions is a citrate salt and/or citric acid is added, the concentration of citrate ion in the aqueous formulation may be in the range 5 to 30mM, preferably 10 to 25mM, particularly preferably 10 to 15mM. A phosphate salt may be used as an alternative buffering agent.
Where the source of sodium (and optionally additional ions) is a chloride salt, the concentration of chloride ion in the aqueous formulation may be in the range 10 to 100mM, preferably 30 to 90mM, more preferably 40 to 85mM, especially preferably 45 to 80mM.
For combatting dehydration as a symptom of severe diarrhoea, higher chloride concentrations are preferred (eg 70-80mM such as about 8Gmbi).
The aqueous formulation of the invention may be an aqueous solution, aqueous dispersion or aqueous suspension. Preferably the aqueous formulation is an aqueous solution. Preferably the aqueous formulation (eg solution) is a reconstituent aqueous formulation (eg solution). For example, a reconstituent aqueous formulation of the invention may be reconstituted by the end user at the point of use from a composition comprising galactose and a source of sodium ions (and optionally one or more sources of additional ions and one or more additional carbohydrates) by addition of a suitable volume of aqueous solvent (eg water).
Viewed from a further aspect the present invention provides a composition formulable (eg dissolvable) in water to form an aqueous formulation as hereinbefore defined, said composition comprising galactose, a source of sodium ions, optionally an ~ additional carbohydrate and optionally a source of additional ions. For example, the composition comprises galactose in an amount sufficient to form a concentration in the range 25 to 135mM in a specified volume of aqueous solvent (eg water) and a source of sodium ions.
The composition of the invention may be provided in any suitable solid or liquid form. For example, the composition may be provided in solid form such as powdered (eg ’ effervescent or non-effervescent powdered) or tablet form or in liquid form such as gel or liquid concentrate form.
Viewed from a yet further aspect the present invention provides the use of galactose and a source of sodium ions for the preparation of (A) an aqueous 25 to 135mM galactose formulation for combatting (eg treating or preventing) dehydration or (B) a medicament formulable (eg dissolvable in water) into an aqueous 25 to 135mM galactose } formulation for combatting (eg treating or preventing) dehydration. : In a preferred embodiment of the use of the invention, the aqueous 25 to 135mM galactose formulation is as hereinbefore defined.
In a preferred embodiment of the use of the invention, the medicament is a composition as hereinbefore defined.
In a preferred embodiment, the present invention provides the use of galactose and a source of sodium ions for the preparation of (A) an aqueous 25 to 135mM galactose formulation for combatting dehydration and associated deficiencies or (B) a medicament formulable into an aqueous 25 to 135mM galactose formulation for combatting dehydration and associated deficiencies. The associated deficiencies may be mineral loss, electrolyte imbalance, etc.
In a preferred embodiment, the present invention provides the use of galactose and a source of sodium ions for the preparation of (A) an aqueous 25 to 135mM galactose formulation for combatting dehydration in children (eg infants) or (B) a medicament formulable into an aqueous 25 to 135mM galactose formulation for combatting og dehydration in children (eg infants).
Preferably the dehydration and (where present) associated deficiencies are symptoms of diarrhoea . The diarrhoea may be a result of (for example) enterotoxin effects
(eg cholera typically in the third world), viral effects (eg rotavirus typically in the developed world) or post surgical rest (eg when GI rest is important). The concentration of each component may be tailored to optimise treatment of dehydration and associated deficiencies causcd by mild, moderate or severe diarrhoea. For combatting dehydration as a symptom of severe diarrhoea, higher sodium and chloride concentrations are preferred.
Alternatively, the circumstances which may lead to dehydration may be self-induced {eg through alcohol consumption).
In a preferred embodiment of the use of the invention, the dehydration or associated deficiencies are life threatening.
Viewed from a still yet further aspect the present invention provides a method for combatting dehydration in a subject comprising the step of: administering an effective dose of an aqueous formulation as hereinbefore defined to the subject.
Viewed from an even still further aspect the present invention provides a method for combatting dehydration and associated deficiencies in a subject comprising the step of: administering an effective dose of an aqueous formulation as hereinbefore defined to the subject.
Although the subject may be any age, preferably the subject is a child (eg an infant). Preferably the dehydration and (where present) associated deficiencies are symptoms of diarrhoea (eg severe diarrhoea). The diarrhoea may be a result of (for example) enterotoxin effects (eg cholera typically in the third world), viral effects (eg rotavirus typically in the developed world) or post surgical rest (eg when GI rest is important). Alternatively, the circumstances which may lead to dehydration may be self- ~ induced (eg through alcohol consumption).
The present invention will now be described in a non-limitative sense with reference to the following Example.
0.
Example ’ Nine reconstituent aqueous formulations A, Al and B-H were prepared which had the components and concentrations after reconstitution in water shown in Table 1:
Table 1 ~ [aew[slc [ole |r ou. [Gon [soo [wo [0 [0 [5 | 5 [5 | 5] owes [sw ww [0 [ss [5 [5
Sodium 45 70 25 30 35 20 25
Chloride
Potassium 25 20 20 15 20 25 20 20 ) Chloride
Trisodium 10 10 10 10 15 13.3/ 10
Citrate/ 6.7
Citric Acid
BE I I OE I I
Frucose | 0 Jo Jo fr fa foo | oo
Sodium BB 15 bicarbonate
A solid mixture of pre-weighed components was prepared such that the specified concentrations were obtained when a certain proportion was dissolved in a specified volume of water. The unit volume of water added to reconstitute the composition may be ’ up to 1000ml. Typically 250ml would be appropriate and a single dose may be made up of ol one, two or three 250ml unit volumes administered at appropriate intervals. Each aqueous formulation may be flavoured to be palatable as desired using lemon, lime, blackcurrant, orange, citrus or cranberry.
The sodium concentration for compositions F, G and H are 60, 40 and 90mM respectively and the chloride concentrations are 45, 45 and 80mM respectively. Higher - sodium and chloride concentrations are desirable for effective treatment of severe diarrhoea. Thus compositions F, G and H are useful in the treatment of moderate, miid and severe diarrhoea respectively.
General purpose formulations 1, J, K, L, M and N are shown in Table 2.
Table 2
I TN I SO I
FE IT I EE RC BC
Glucose - - 60 60 - -
Sodium 30 30 30
Chloride
Potassium 20 20 20 20 20 20
Chloride
Trisodium 13.3/ 13.3/ - 13.3/
Citrate/ 6.7 6.7 6.7 !
Citric Acid
Maltodextrin 10 10 (chain 6)
Claims (37)
- ’ 1. An aqueous formulation for combatting dehydration comprising galactose at a concentration in the range 25 to 135mM, a source of sodium ions and water. lo
- 2. An aqueous formulation as claimed in claim 1 wherein the concentration of galactose in the aqueous formulation is in the range 25 to 130mM.
- 3. An aqueous formulation as claimed in claim 1 or 2 wherein the concentration of galactose in the aqueous formulation is in the range 37 to 120mM, .
- 4. An aqueous formulation as claimed in any preceding claim wherein the concentration of galactose in the aqueous formulation is in the range 40 to 120mM.
- 5. An aqueous formulation as claimed in any preceding claim wherein the source of sodium ions is sodium chloride optionally together with sodium citrate.
- 6. An aqueous formulation as claimed in any preceding claim wherein the concentration of sodium ions in the aqueous formulation is in the range 25 to 100mM.
- 7. An aqueous formulation as claimed in any preceding claim wherein the concentration of sodium ions in the aqueous formulation is in the range 30 to 90mM.
- 8. An aqueous formulation as claimed in any preceding claim wherein the concentration of sodium ions in the aqueous formulation is in the range 35 to 90mM.
- 9. An aqueous formulation as claimed in any preceding claim wherein the concentration of ’ sodium ions in the aqueous formulation is in the range 45 to 90mM. A]
- 10. An aqueous formulation as claimed in any preceding claim wherein the concentration of sodium ions in the aqueous formulation is in the range 60 to 90mM.
- 11. An aqueous formulation as claimed in any preceding claim further comprising a source of potassium ions at a concentration in the aqueous formulation in the range 20 to 25mM.
- 12. An aqueous formulation as claimed in any preceding claim further Comprising one or more additional carbohydrates selected from the group consisting of glucose, sucrose, dextrose, fructose, lactose and maltose.
- 13. An aqueous formulation as claimed in any preceding claim wherein the total concentration of carbohydrate is in the range 50 to 300mM.
- 14. An aqueous formulation as claimed in any preceding claim wherein the total concentration of carbohydrate is in the range 50 to 200mM
- 15. An aqueous formulation as claimed in any preceding claim wherein the total concentration of carbohydrate is in the range 55 to 175mM.
- 16. An aqueous formulation as claimed in any preceding claim wherein the total concentration of carbohydrate is in the range 60 to 135mM
- 17. An aqueous formulation as claimed in any preceding claim wherein the total concentration of carbohydrate is in the range 90 to 130mM.
- 18. An aqueous formulation as claimed in any of claims 12 to 17 wherein galactose and glucose are present in a total amount sufficient to meet the carbohydrate requirements of sodium co-transport in effective rehydration and the ratio of molar concentration of galactose and glucose is in the range 0.6:1 to 1:0.6.
- 19. An aqueous formulation as claimed in claim 18 wherein the ratio of molar concentration of galactose and glucose is in the range 0.8:1 to 1:0.8. ~~~
- 20. An aqueous formulation as claimed in claim 18 or 19 wherein the ratio of molar concentration of galactose and glucose is in the range 0.9:1 to 1:0.9.’ ’ ( iE i
- 21. An aqueous formulation as claimed in any of claims 18 to 20 wherein the ratio of molar concentration of galactose and glucose is about 1:1.
- 22. An aqueous formulation as claimed in any of claims 12 to 21 wherein the - concentration of glucose in the aqueous formulation is in the range 30 to 135mM.
- 23. An aqueous formulation as claimed in any of claims 12 to 22 wherein the concentration of glucose in the aqueous formulation is in the range 35 to 130mM
- 24. An aqueous formulation as claimed in any of claims 12 to 23 wherein the concentration of glucose in the aqueous formulation is in the range 37 to 120mM
- 25. An aqueous formulation as claimed in any of claims 12 to 24 wherein the . concentration of glucose in the aqueous formulation is in the range 40 to 100mM )
- 26. An aqueous formulation as claimed as claimed in any of claims 12 to 25 wherein the concentration of glucose in the aqueous formulation is in the range 45 to 80mM.
- 27. An aqueous formulation as claimed in any preceding claim wherein the concentration of glucose is satisfied at least in part by a glucosidic oligosaccharide.
- 28. An aqueous formulation as claimed in claim 27 wherein the glucosidic oligosaccharide is maltodextrin.
- 29. A composition formulable in water to form an aqueous formulation as defined in any preceding claim, said composition comprising galactose, a source of sodium ions, optionally an additional carbohydrate and optionally a source of additional ions. 4
- 30. Use of galactose and a source of sodium ions for the preparation of (A) an aqueous 25 to 135mM galactose formulation for combatting dehydration or (B) a medicament formulable into an aqueous 25 to 135mM galactose formulation for combatting dehydration.
- 31. Use as claimed in claim 30 of galactose and a source of sodium ions for the preparation of (A) an aqueous 25 to 135mM galactose formulation for combatting dehydration in children or (B) a medicament formulable into an aqueous 25 to 135mM : galactose formulation for combatting dehydration in children.
- 32. Use as claimed in claim 30 or 31 wherein the dehydration is a symptom of diarrhoea.
- 33. An aqueous formulation as defined in any of claims 1 to 28 for use in combating dehydration in a subject. :
- 34. Use of an aqueous formulation as defined in any of claims 1 to 28 in the manufacture of a medicament for combating dehydration.
- 35. An aqueous formulation as claimed in claim 1, substantially as herein described and exemplified..
- 36. A composition formulable in water to form an aqueous formulation as claimed in claim 29, substantially as herein described and exemplified.
- 37. Use as claimed in claim 30 or claim 34, substantially as herein described and exemplified. : AMENDED SHEET ,
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0126746.7A GB0126746D0 (en) | 2001-11-07 | 2001-11-07 | Rehydrating formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200403278B true ZA200403278B (en) | 2005-01-12 |
Family
ID=9925340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200403278A ZA200403278B (en) | 2001-11-07 | 2004-04-30 | Rehydrating formulation. |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1441741A1 (en) |
JP (1) | JP2005508984A (en) |
CN (1) | CN1582157A (en) |
AP (1) | AP2004003051A0 (en) |
BR (1) | BR0213942A (en) |
CA (1) | CA2466278A1 (en) |
EA (1) | EA200400636A1 (en) |
GB (1) | GB0126746D0 (en) |
MX (1) | MXPA04004339A (en) |
OA (1) | OA13061A (en) |
ZA (1) | ZA200403278B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI721961B (en) * | 2014-12-26 | 2021-03-21 | 日商明治股份有限公司 | Supplemental liquid comprising dietary fiber |
CN108777978A (en) * | 2016-03-04 | 2018-11-09 | 鹫尾伸人 | Beverage product and method and apparatus for manufacturing beverage product |
-
2001
- 2001-11-07 GB GBGB0126746.7A patent/GB0126746D0/en not_active Ceased
-
2002
- 2002-11-04 JP JP2003541847A patent/JP2005508984A/en active Pending
- 2002-11-04 EA EA200400636A patent/EA200400636A1/en unknown
- 2002-11-04 CN CNA028220102A patent/CN1582157A/en active Pending
- 2002-11-04 BR BR0213942-1A patent/BR0213942A/en not_active Application Discontinuation
- 2002-11-04 AP APAP/P/2004/003051A patent/AP2004003051A0/en unknown
- 2002-11-04 EP EP02779653A patent/EP1441741A1/en not_active Withdrawn
- 2002-11-04 MX MXPA04004339A patent/MXPA04004339A/en unknown
- 2002-11-04 OA OA1200400128A patent/OA13061A/en unknown
- 2002-11-04 CA CA002466278A patent/CA2466278A1/en not_active Abandoned
-
2004
- 2004-04-30 ZA ZA200403278A patent/ZA200403278B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1441741A1 (en) | 2004-08-04 |
EA200400636A1 (en) | 2004-12-30 |
OA13061A (en) | 2006-11-10 |
AP2004003051A0 (en) | 2004-06-30 |
BR0213942A (en) | 2004-09-08 |
JP2005508984A (en) | 2005-04-07 |
MXPA04004339A (en) | 2005-05-16 |
CA2466278A1 (en) | 2003-05-15 |
GB0126746D0 (en) | 2002-01-02 |
CN1582157A (en) | 2005-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU686338B2 (en) | Sports drink | |
US5114723A (en) | Beverage compositions for human consumption | |
US5032411A (en) | Beverage compositions for human consumption | |
US20200268790A1 (en) | Electrolyte purgative | |
US7566463B2 (en) | Oral rehydration compositions | |
CA2373473C (en) | Electrolyte gels for maintaining hydration and rehydration | |
Lifshitz et al. | Oral hydration solutions: experimental optimization of water and sodium absorption | |
WO2014093999A2 (en) | Alkaline drink | |
US20060172016A1 (en) | Muscle cramp reliever | |
EP1555897B1 (en) | Ergogenic multivitamin-mineral energy supplement for the prevention of muscle fatigue | |
US20030134804A1 (en) | Rehydrating formulation | |
ZA200403278B (en) | Rehydrating formulation. | |
WO2003039556A1 (en) | Rehydrating formulation | |
US20050048136A1 (en) | Rehydrating beverage with Rhodiola crenulata and D-ribose that enhances blood oxygen and relieves post-exertional muscle cramping and soreness | |
AU2002342995A1 (en) | Rehydrating formulation | |
EP1489925A1 (en) | Composition comprising phosphate | |
JP2007314560A (en) | Agent for keeping oxidative metabolism caused by exercise | |
Behrens | The impact of oral rehydration and other therapies on the management of acute diarrhoea | |
US20150351443A1 (en) | Hydrating compositions | |
Bucens et al. | Hypernatraemic dehydration after Lucozade | |
WO2004004740A1 (en) | Aqueous formulation comprising digestible saccharides to reduce the tendency to cardiovascular disease in a subject | |
WO2004004741A1 (en) | Aqueous formulation comprising digestible saccharides with beneficial effects on a tendency to cardiovascular disease | |
AU2003205450B2 (en) | Electrolyte purgative | |
AU2003205450C1 (en) | Electrolyte purgative | |
Wassner | 29 in Nutrition renal disease |